ErbB receptors as prognostic and therapeutic drug targets in bone and soft tissue sarcomas.

Abstract

ErbB receptors have been intensely studied to understand their importance in cancer biology and as therapeutic targets, and many ErbB inhibitors are now used in the clinical setting. A large number of studies have been conducted to examine the expression of ErbB family members in bone and soft tissue sarcomas, including osteosarcomas, synovial sarcomas, Ewing sarcomas, rhabdomyosarcomas, and so on. Nevertheless, the clinical implications of ErbB receptors remain elusive. To illustrate the potential of ErbB family members as prognostic and therapeutic drug targets in bone and soft tissue sarcomas, we summarized the molecular evidence and observations from clinical and basic trials.

DOI: 10.3109/07357907.2014.964409

Statistics

0500201520162017
Citations per Year

84 Citations

Semantic Scholar estimates that this publication has 84 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Wang2014ErbBRA, title={ErbB receptors as prognostic and therapeutic drug targets in bone and soft tissue sarcomas.}, author={Hongsheng Wang and Qingbo Yang and Zeze Fu and Dongqing Zuo and Yingqi Hua and Zheng-dong Cai}, journal={Cancer investigation}, year={2014}, volume={32 10}, pages={533-42} }